Nektar Therapeutics | NKTR - Debt


Nektar Therapeutics reported $0 in Debt for its fiscal quarter ending in June of 2022.





Debt Change Date
Agios Pharmaceuticals USD 40.21M 4.31M Dec/2025
ALKERMES USD 1.58B 1.51B Mar/2026
Alterity Therapeutics Limited AUD 210.39K 120.67K Jun/2023
Amgen USD 54.6B 17M Dec/2025
Baxter International USD 9.78B 68M Dec/2025
BioCryst Pharmaceuticals USD 828.6M 510K Dec/2024
Biogen USD 6.56B 275.1M Mar/2026
Bristol-Myers Squibb USD 47.14B 3.9B Dec/2025
Cara Therapeutics USD 0 0 Mar/2025
Cipla INR 6.14B 1.76B Mar/2026
Dr.Reddys Laboratories INR 77.34B 9.61B Mar/2026
Eisai JPY 236.67B 49.14B Sep/2025
Eli Lilly USD 42.5B 3.6M Dec/2025
Exelixis USD 169.54M 3.5M Mar/2026
Gilead Sciences USD 24.94B 5M Dec/2025
GlaxoSmithKline GBP 19.06B 1.34B Mar/2026
Grifols EUR 9.23B 626.05M Dec/2024
Halozyme Therapeutics USD 2.14B 2.01M Mar/2026
Incyte USD 39.43M 982K Mar/2026
Ionis Pharmaceuticals USD 2.34B 9.5M Mar/2026
Ironwood Pharmaceuticals USD 583.99M 14.83M Dec/2024
Karyopharm Therapeutics USD 299.23M 35.14M Dec/2025
MacroGenics USD 36.51M 500K Mar/2026
Merck USD 49.34B 7.97B Dec/2025
Nektar Therapeutics USD 0 0 Jun/2022
Neurocrine Biosciences USD 406.2M 9.1M Mar/2026
Novartis USD 47B 11.62B Mar/2026
Pfizer USD 63.73B 231M Mar/2026
Roche Holding CHF 33.03B 1.41B Jun/2025
Sarepta Therapeutics USD 1.04B 210.44M Dec/2025
Takeda JPY 4.85T 208B Dec/2025
Teva Pharmaceutical Industries USD 17.09B 21M Dec/2025
Xencor USD 187.75M 118.48M Dec/2025